ThanhC.ChengMD

Emergency Medicine • Pearland, TX

Emergency Medicine Physician and Principal Investigator in Stem Cell Clinical Trials

Join to view full profile

Dr. Cheng is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Cheng's full profile

Already have an account?

Office
2752 Sunrise Blvd
Pearland, TX 77584
Phone+1 713-766-1096

Summary

Dr. Thanh Cheng is an emergency medicine physician in Humble, TX and is affiliated with SE Texas ER & Hospital. He received his medical degree from Vanderbilt University School of Medicine and has been in practice 26 years in emergency medicine. He is also a principal investigator in FDA-approved mesenchymal stem-cell clinical trials for various diseases at Hope Biosciences.

Education & Training

West Virginia UniversityResidency, Emergency Medicine, 1995 - 1998
Vanderbilt University School of MedicineClass of 1995

Certifications & Licensure

TX State Medical License 1998 - 2025
FL State Medical License 2002 - 2005
CA State Medical License 2001 - 2003
WV State Medical License 1998 - 2000
American Board of Emergency Medicine Emergency Medicine

Clinical Trials

A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs Against COVID-19. Start of enrollment: 2020 May 14
Completed
Phase 2
A Clinical Trial to Determine the Safety and Efficacy of HB-adMSCs to Provide Protection Against COVID-19 Start of enrollment: 2020 Apr 20
Completed
Phase 2
Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome Start of enrollment: 2022 Jan 06
Completed
Phase 2
Individual Patient Expanded Access IND of Autologous HB-adMSCs for the Treatment of Systemic Lupus Erythematosus (SLE)
No longer available
Intermediate Size Expanded Access Protocol for the Treatment of Post-COVID-19 Syndrome
No longer available
Individual Patient Expanded Access IND to Treat Polyneuropathy
No longer available
Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD) Start of enrollment: 2021 Jul 16
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

3 citations
Adipose-derived, autologous mesenchymal stem cell therapy for patients with post-COVID-19 syndrome: an intermediate-size expanded access program.
Ridhima Vij, Hosu Kim, Hyeonggeun Park, Thanh Cheng, Djamchid Lotfi
Stem Cell Research & Therapy. 2023-10-05
1 citations
Long-term, repeated doses of intravenous autologous mesenchymal stem cells for a patient with Parkinson's disease: a case report.
Ridhima Vij, Alan Prossin, Mallika Tripathy, Hosu Kim, Hyeonggeun Park
Frontiers in Neurology. 2023-01-01
1 citations
Frequency-dependent effect of intravenous administration of human adipose-derived mesenchymal stem cell therapy for severe Systemic Lupus Erythematosus: A case report.
Ridhima Vij, Mallika Tripathy, Hosu Kim, Hyeonggeun Park, Thanh Cheng
Journal of Translational Autoimmunity. 2022-01-01

External Links

Linked inhttp://www.linkedin.com/in/thanh-c-61400619